Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 21;4(1):13.
doi: 10.1186/s44158-024-00150-w.

Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review

Irene Coloretti  1 , Andrea Genovese  2 , J Pedro Teixeira  3 , Anusha Cherian  4 , Ricard Ferrer  5 , Giovanni Landoni  6 , Marc Leone  7 , Massimo Girardis  2 , Nathan D Nielsen  8
Affiliations
Review

Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review

Irene Coloretti et al. J Anesth Analg Crit Care. .

Abstract

Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use.

Keywords: Angiotensin II; Refractory shock; Septic shock; Vasopressors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Clinical indications for considering the use of Angiotensin II in critically ill patients with septic shock or other distributive shock (left). Dose and clinical effects in specific sub-populations of Angiotensin II therapy (right)
See this image and copyright information in PMC

References

    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. 10.1001/jama.2016.0287 - PMC - PubMed
    1. Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND et al (2023) Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care 75:154258. 10.1016/j.jcrc.2023.154258 - PubMed
    1. Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H et al (2018) The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med 44:857–867. 10.1007/s00134-018-5218-5 - PMC - PubMed
    1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:e1063–e1143. 10.1097/CCM.0000000000005337 - PubMed
    1. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34:2226–2234. 10.1007/s00134-008-1219-0 - PubMed

LinkOut - more resources